Format

Send to

Choose Destination
Int J Hematol. 2011 Jun;93(6):779-781. doi: 10.1007/s12185-011-0870-3. Epub 2011 May 11.

CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.

Author information

1
Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho Showa-ku, Nagoya, Aichi, 466-8650, Japan.
2
Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Aichi, Japan.
3
Department of Pathology, Japanese Red Cross Nagoya First Hospital, Aichi, Japan.
4
Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho Showa-ku, Nagoya, Aichi, 466-8650, Japan. kojimas@med.nagoya-u.ac.jp.

Abstract

Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.

PMID:
21559814
DOI:
10.1007/s12185-011-0870-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center